GLPG1205

January 27, 2016May 17, 2016

Development of Drug for Ulcerative Colitis to Be Discontinued, Company Reports

News

Belgium-based Galapagos NV has announced it is discontinuing its clinical development of drug candidate GLPG1205 for ulcerative colitis because an important part of the clinical trial — endpoints for efficacy — were not met. The ... Read more

June 19, 2015June 19, 2015

Galapagos Finishes Enrollment of Patients with Ulcerative Colitis for IBD Trial

News, Ulcerative colitis

Galapagos NV recently announced that the company has completed recruitment of patients with ulcerative colitis for its phase 2 proof-of-concept study designed to evaluate GLPG1205 as a possible therapy for inflammatory bowel diseases (IBD). Galapagos ... Read more

January 13, 2015January 13, 2015

Galapagos Initiates IBD Therapy Trial on Ulcerative Colitis Patients

News, Ulcerative colitis

Galapagos NV has started a phase 2 Proof-of-Concept study to evaluate a potential novel therapy, a GPR84 inhibitor called GLPG1205 that is being studied in patients who suffer from ulcerative colitis. The ... Read more